<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="nanomaterials-10-01072-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">nanomaterials-10-01072-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Summary of developed nanoparticulate drug delivery systems towards treatment and/or therapy of viral infections.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Nanoplatform</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Properties (Shape/Size/Toxicity)</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="12" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
     <bold>NPs</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Silver (Ag)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monodisperse and uniformly spherical; highly stable Ag@AM (2 nm &gt; 28 days); Ag NPs loaded with AM on their surface less cytotoxic (~90%) than free AgNPs (65%) or AM (56%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Amantadine (AM)</td>
    <td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">H1N1</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B30-nanomaterials-10-01072" ref-type="bibr">30</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Selenium (Se)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical Se@AM (70 nm)—more stable, superior antiviral effect on kidney cells treated with H1N1 and less cytotoxicity (79.26% viability) than SeNPs (200 nm, 58.8%) and/or free AM (53.23%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AM</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B31-nanomaterials-10-01072" ref-type="bibr">31</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical Se@OTV (100 nm)—superior antiviral effect on kidney cells treated with H1N1 and less cytotoxicity (93% viability) than SeNPs (60%) and/or free OTV (53%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oseltamivir (OTV)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B32-nanomaterials-10-01072" ref-type="bibr">32</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical shape; NPs (178 nm &amp; 197 nm) loaded with diphyllin and bafilomycin; high biocompatibility and antiviral activity towards the NP drugs than the free drugs</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diphyllin &amp; Bafilomycin</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B33-nanomaterials-10-01072" ref-type="bibr">33</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniform, spherical/smooth surface NPs (116−143 nm); three GCV pro-drugs can be separately loaded on PLGA NPs; non-cytotoxic PLGA NPs (24 h and 48 h contact of three diverse NPs concentrations with HCEC cell)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gangiclovir (GCV)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV 
     <sup>a</sup> -1
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B34-nanomaterials-10-01072" ref-type="bibr">34</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HPAC</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99% drug loading efficiency; HPAC (diverse concentrations)—non-cytotoxic towards human epithelial cells (vaginal, corneal), foreskin fibroblasts, HeLa cells: cell viability &gt;75%</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acyclovir (ACV)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B35-nanomaterials-10-01072" ref-type="bibr">35</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polydisperse particles loaded with LAM (221−250 nm); slow NPs degradation in simulated intestinal fluid PBS; the molecular interaction between polymer and LAM confirmed by FTIR and DSC</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lamivudine (LAM)</td>
    <td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B36-nanomaterials-10-01072" ref-type="bibr">36</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical/smooth surface NFV NPs (~185 nm); almost narrow distribution</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efavirenz (EFV)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B37-nanomaterials-10-01072" ref-type="bibr">37</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEO-PCL</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical PEO-PCL NPs (~200−270 nm)with smooth surface; SQV is encapsulated into NPs</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saquinavir (SQV)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B38-nanomaterials-10-01072" ref-type="bibr">38</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA-PEG</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical shape (~125 nm) for those loaded with SAHA and NFV; ~119 nm for those loaded with SAHA; ~118 nm for NPs loaded with NFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Suberoylanilide hydroxamic acid (SAHA) and NFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B39-nanomaterials-10-01072" ref-type="bibr">39</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hybrid NPs (PLGA, PLA, MMA-SPM, and PMMA)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Almost spherical NPs; PLGA NPs (58~224 nm) and MMA-SPM NPs (91−823 nm); nontoxic NPs (male mice)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LAM+AZT (Zidovudine)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B40-nanomaterials-10-01072" ref-type="bibr">40</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PMA coated MNP</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uniformly spherical NPs conjugated with ENF (35.2 nm); nontoxic in vivo and in vitro NPs conjugated with ENF</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enfuvirtide (ENF)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B41-nanomaterials-10-01072" ref-type="bibr">41</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Nanospheres (NS)</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan (Cs)</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spherical NS (~200 nm diameter) with smooth surface; polydisperse NS; after contact with NS has a satisfactory Vero cell viability; 86% ACV encapsulation efficiency</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B42-nanomaterials-10-01072" ref-type="bibr">42</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Dendrimers</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PG 
     <sup>b</sup>
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral effect in vitro; nontoxic peptide-PG conjugates in vitro</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptides</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IAV 
     <sup>c</sup>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B43-nanomaterials-10-01072" ref-type="bibr">43</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
     <bold>Lipid NPs (LNPs)</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DSPC 
     <sup>d</sup> +MPEG+DSPE
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNPs (52~68 nm); in vivo antiHIV LNPS do not display local reactions, and also animal platelet counts were within normal limits</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LPV 
     <sup>e</sup> +TFV 
     <sup>f</sup> +RTV 
     <sup>g</sup>
    </td>
    <td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B44-nanomaterials-10-01072" ref-type="bibr">44</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG and phospholipids</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LNPs loaded with drug or drugs (33~68 nm); incorporation efficiency (88~96%)</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ATV 
     <sup>h</sup> +TFV+RTV
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B45-nanomaterials-10-01072" ref-type="bibr">45</xref>]
    </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>Micelles</bold>
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cs-
     <italic>g</italic>-oligo(NiPAam)
    </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Copolymers self-assembled in multimicellar aggregates by hydrodynamic (330~436 nm); high mucoadhesion and cytocompatibility properties</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EFV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B46-nanomaterials-10-01072" ref-type="bibr">46</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <sup>a</sup> Herpes simplex virus; 
    <sup>b</sup> polyglycerol; 
    <sup>c</sup> influenza A virus; 
    <sup>d</sup> 1,2-Distearoyl-sn-glycero-3-phosphocholine; 
    <sup>e</sup> Lopinavir (LPV); 
    <sup>f</sup> Tenofovir; 
    <sup>g</sup> Ritonavir; 
    <sup>h</sup> Atazanavir.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
